SCHEMBL10288236

SCHEMBL10288236

COc1ccc2c(c1)C(=CCCN1CCC(O)(c3ccc(Cl)cc3)CC1)C1C=CC=NC1CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ DRD2 P14416 5/20 0.39
▸ DRD3 P35462 2/20 0.39
▸ CCR1 P32246 3/20 0.39
▸ SIGMAR1 Q99720 2/20 0.38
▸ DRD1 P21728 3/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ DRD5 P21918 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ HRH1 P35367 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ SLC6A1 P30531 1/20 0.35
▸ SLC6A12 P48065 1/20 0.35
▸ SLC6A11 P48066 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13824429 0.97 ALDH1A1 (0.39) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL10287529 0.93 SLC6A1 (0.36) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL10287957 0.93 SIGMAR1 (0.37) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL13617254 0.93 DRD2 (0.36) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL12121683 0.93 SIGMAR1 (0.38) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL13617080 0.92 DRD2 (0.36) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL10287605 0.92 DRD2 (0.41) DRD2DRD3CCR1DRD1HTR1A
SCHEMBL10288248 0.92 DRD2 (0.40) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL12121526 0.91 SIGMAR1 (0.34) ALDH1A1LMNANPC1RAB9ADRD2
SCHEMBL10288249 0.91 CCR1 (0.36) ALDH1A1LMNANPC1RAB9ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046311-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF KYOWA HAKKO KOGYO CO., LTD. (JP) 2012-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046311-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF ACKR3, CCR2, CXCR2 ALDH1A1 2146/4885LMNA 4626/4885NPC1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback